Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling

INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Lung Cancer
Prif Awduron: Le, Xiuning, Freed, Jason A., VanderLaan, Paul A., Huberman, Mark S., Rangachari, Deepa, Jorge, Susan E., Lucena-Araujo, Antonio R., Kobayashi, Susumu S., Balasubramanian, Sohail, He, Jie, Chudnovksy, Yakov, Miller, Vincent A., Ali, Siraj M., Costa, Daniel B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/
https://ncbi.nlm.nih.gov/pubmed/25922291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg